Comparison of 8 vs 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults: A Randomized Trial

JAMA

Volumn 290, Issue 19, 2003, Pages 2588-2598

  Chastre, Jean ^a   Wolff, Michel ^k   Fagon, Jean Yves ^k   Chevret, Sylvie ^b   Thomas, Franck ^c   Wermert, Delphine ^d   Clementi, Eva ^e   Gonzalez, Jesus ^f   Jusserand, Dominique ^g   Asfar, Pierre ^h   Perrin, Dominique ⁱ   Fieux, Fabienne ^b   Aubas, Sylvie ^j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Hopital des Diaconesses   (France)

^d BICÊTRE HOSPITAL   (France)

^e Hôpital Les Audaries   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ Hôpital Courcouronne   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; EVALUATION; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 0345283255     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.19.2588     Document Type: Article

References (41)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999;27:520-532.
2. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2: Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29:245-252.
3. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298-314.
4. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-888.
5. Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064-1073.
6. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002;162:1515-1520.
7. Mahgoub S, Ahmed J, Glatt AE. Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol. 2002;23:477-479.
8. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Weekly Rep. 2002;51:565-567.
9. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA. 1996;275:234-240.
10. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25:584-599.
11. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A. 2000;97:1938-1943.
12. Lawton RM, Fridkin SK, Gaynes RP, McGowan JE Jr. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations: Society for Healthcare Epidemiology of America/ Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 2000;21:256-259.
13. Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA. 1996;275:866-869.
14. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA. 1995;274:639-644.
15. Bergmans DC, Bonten MJ, Gaillard CA, et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997;39:527-535.
16. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 1996;153:1711-1725.
17. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867-903.
18. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother. 1994;38:547-557.
19. Rello J, Mariscal D, March F, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med. 1998;157:912-916.
20. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia: criteria for evaluating diagnostic techniques. Chest. 1992;102(suppl 5):553S-556S.
21. Wunderink RG, Mayhall CG, Gibert C. Methodology for clinical investigation of ventilator-associated pneumonia: epidemiology and therapeutic intervention. Chest. 1992;102(suppl 1):580S-588S.
22. Chastre J, Fagon JY, Bornet-Lecso M, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med. 1995;152:231-240.
23. Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev. 1994;7:533-558.
24. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109-1115.
25. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531-539.
26. McCabe WR, Jackson GJ. Gram-negative bacteremia, 1: etiology and ecology. Arch Intern Med. 1962;110:847-864.
27. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-2963.
28. Vincent JL, Moreno R, Takala J, et al, On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707-710.
29. Fagon JY, Chastre J, Novara A, Medioni P, Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med. 1993;19:137-144.
30. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101:1481-1483.
31. Bernard GR, Artigas A, Brigham KL, et al, The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-824.
32. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med. 2000;132:621-630.
33. Durrleman S, Simon R. Planning and monitoring of equivalence studies. Biometrics. 1990;46:329-336.
34. Jennison C, Turnbull BW. Repeated confidence intervals for group sequential clinical trials. Control Clin Trials. 1984;5:33-45.
35. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348-361.
36. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41:361-372.
37. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920-2925.
38. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
39. Combes A, Figliolini C, Trouillet JL, et al. Factors predicting ventilator-associated pneumonia recurrence. Crit Care Med. 2003;31:1102-1107.
40. Dennesen PJ, van Der VA, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001;163:1371-1375.
41. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505-511.